Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
QuintilesIMS
McKinsey
Johnson and Johnson
Moodys
Dow
Healthtrust
Argus Health
Merck

Generated: October 20, 2017

DrugPatentWatch Database Preview

Arbor Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ARBOR PHARMS LLC, and when can generic versions of ARBOR PHARMS LLC drugs launch?

ARBOR PHARMS LLC has twenty-one approved drugs.

There are nineteen US patents protecting ARBOR PHARMS LLC drugs.

There are two hundred and sixty-eight patent family members on ARBOR PHARMS LLC drugs in forty-two countries and twenty-four supplementary protection certificates in fourteen countries.

Summary for Applicant: Arbor Pharms Llc

International Patents:268
US Patents:19
Tradenames:22
Ingredients:14
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc
CETYLEV
acetylcysteine
TABLET, EFFERVESCENT;ORAL207916-001Jan 29, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
ERYTHROCIN STEARATE
erythromycin stearate
TABLET;ORAL060359-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Arbor Pharms Llc
CETYLEV
acetylcysteine
TABLET, EFFERVESCENT;ORAL207916-002Jan 29, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Arbor Pharms Llc
ERYPED
erythromycin ethylsuccinate
GRANULE;ORAL050207-003Mar 30, 1987ABRXYesNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
PCE
erythromycin
TABLET, COATED PARTICLES;ORAL050611-001Sep 9, 1986RXYesNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
ERYTHROMYCIN
erythromycin
CAPSULE, DELAYED REL PELLETS;ORAL062746-001Dec 22, 1986ABRXNoNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
ERY-TAB
erythromycin
TABLET, DELAYED RELEASE;ORAL062298-001Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe
Arbor Pharms Llc
PEDIAMYCIN
erythromycin ethylsuccinate
SUSPENSION;ORAL062304-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Arbor Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
GLIADEL
carmustine
IMPLANT;INTRACRANIAL020637-001Sep 23, 1996► Subscribe► Subscribe
Arbor Pharms Llc
BIDIL
hydralazine hydrochloride; isosorbide dinitrate
TABLET;ORAL020727-001Jun 23, 2005► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
GLIADEL
carmustine
IMPLANT;INTRACRANIAL020637-001Sep 23, 1996► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBYCLOR
azilsartan kamedoxomil; chlorthalidone
TABLET;ORAL202331-001Dec 20, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 2011► Subscribe► Subscribe
Arbor Pharms Llc
EDARBYCLOR
azilsartan kamedoxomil; chlorthalidone
TABLET;ORAL202331-002Dec 20, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Arbor Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,423,169Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity► Subscribe
8,367,722Methods of using prodrugs of pregabalin► Subscribe
8,906,412GABA analog prodrug sustained release oral dosage forms► Subscribe
9,238,616Prodrugs of gaba analogs, compositions and uses thereof► Subscribe
7,186,855Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
9,150,503Crystalline form of .gamma.-aminobutyric acid analog► Subscribe
7,232,924Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
7,790,708Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
6,972,341 Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Arbor Pharms Llc Drugs

Country Document Number Estimated Expiration
Costa Rica20110111► Subscribe
Malaysia142807► Subscribe
China101677961► Subscribe
Norway20083956► Subscribe
World Intellectual Property Organization (WIPO)2004052844► Subscribe
Uruguay32017► Subscribe
Portugal1718641► Subscribe
Norway338688► Subscribe
Tunisia2011000045► Subscribe
Norway20061655► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Arbor Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00756Netherlands► SubscribePRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN; NAT. REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MA117/01101 20150402
6Finland► Subscribe
C0034France► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207
2012004,C1718641Lithuania► SubscribePRODUCT NAME: AZILSARTANUM MEDOXOMILUM; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/734/011, 2011 12 07, EU/1/11/735/001 - EU/1/11/735/011 20111207
00525Netherlands► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCHE AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; REGISTRATION NO/DATE: EU/1/11/734/001-011EU/1/11/735/001-011 2011071207
962Luxembourg► Subscribe91962, EXPIRES: 20261207
1 5004-2012Slovakia► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/735/011 20111207
2015000079Germany► SubscribePRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402
C0069France► SubscribePRODUCT NAME: IVERMECTINE; NAT. REGISTRATION NO/DATE: NL 44511 20150721; FIRST REGISTRATION: MT - MA 117/01101 20150402
/2015Austria► SubscribePRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Covington
Julphar
Harvard Business School
McKesson
Cerilliant
QuintilesIMS
Johnson and Johnson
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot